Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders.

Navalpotro-Gomez I, Kim J, Paz-Alonso PM, Delgado-Alvarado M, Quiroga-Varela A, Jimenez-Urbieta H, Carreiras M, Strafella AP, Rodriguez-Oroz MC.

Parkinsonism Relat Disord. 2019 Dec 16;70:74-81. doi: 10.1016/j.parkreldis.2019.12.009. [Epub ahead of print]

PMID:
31881521
2.

Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

Pontone GM, Dissanayka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z.

NPJ Parkinsons Dis. 2019 Dec 11;5:30. doi: 10.1038/s41531-019-0102-8. eCollection 2019. Review.

3.

Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.

Lizarraga KJ, Fox SH, Strafella AP, Lang AE.

Clin Geriatr Med. 2020 Feb;36(1):105-118. doi: 10.1016/j.cger.2019.09.004. Epub 2019 Sep 6. Review.

PMID:
31733691
4.

The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson's Disease.

Ghadery C, Koshimori Y, Christopher L, Kim J, Rusjan P, Lang AE, Houle S, Strafella AP.

Mol Neurobiol. 2020 Jan;57(1):492-501. doi: 10.1007/s12035-019-01714-6. Epub 2019 Aug 5.

PMID:
31385228
5.

Imaging tools to map in vivo the human brain.

Strafella AP.

Mov Disord. 2019 Jul;34(7):931-933. doi: 10.1002/mds.27732. No abstract available.

PMID:
31322772
6.

Dynamic functional connectivity changes associated with dementia in Parkinson's disease.

Fiorenzato E, Strafella AP, Kim J, Schifano R, Weis L, Antonini A, Biundo R.

Brain. 2019 Sep 1;142(9):2860-2872. doi: 10.1093/brain/awz192.

PMID:
31280293
7.

The clinical significance of lower limb tremors.

Rajalingam R, Breen DP, Chen R, Fox S, Kalia LV, Munhoz RP, Slow E, Strafella AP, Lang AE, Fasano A.

Parkinsonism Relat Disord. 2019 Aug;65:165-171. doi: 10.1016/j.parkreldis.2019.06.007. Epub 2019 Jun 8.

PMID:
31201091
8.

PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases.

Ghadery C, Best LA, Pavese N, Tai YF, Strafella AP.

Curr Neurol Neurosci Rep. 2019 May 28;19(7):38. doi: 10.1007/s11910-019-0951-x. Review.

9.

Network Patterns of Beta-Amyloid Deposition in Parkinson's Disease.

Kim J, Ghadery C, Cho SS, Mihaescu A, Christopher L, Valli M, Houle S, Strafella AP.

Mol Neurobiol. 2019 Nov;56(11):7731-7740. doi: 10.1007/s12035-019-1625-z. Epub 2019 May 20.

PMID:
31111400
10.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

11.

New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.

Best L, Ghadery C, Pavese N, Tai YF, Strafella AP.

Curr Neurol Neurosci Rep. 2019 Apr 2;19(5):24. doi: 10.1007/s11910-019-0934-y. Review.

PMID:
30941587
12.

DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.

Valli M, Cho SS, Masellis M, Chen R, Rusjan P, Kim J, Koshimori Y, Mihaescu A, Strafella AP.

Mol Neurobiol. 2019 Sep;56(9):6512-6520. doi: 10.1007/s12035-019-1543-0. Epub 2019 Mar 8.

PMID:
30847741
13.

Motor Synchronization to Rhythmic Auditory Stimulation (RAS) Attenuates Dopaminergic Responses in Ventral Striatum in Young Healthy Adults: [11C]-(+)-PHNO PET Study.

Koshimori Y, Strafella AP, Valli M, Sharma V, Cho SS, Houle S, Thaut MH.

Front Neurosci. 2019 Feb 14;13:106. doi: 10.3389/fnins.2019.00106. eCollection 2019.

14.

Mesolimbic dopamine and anterior cingulate cortex connectivity changes lead to impulsive behaviour in Parkinson's disease.

Strafella AP.

Brain. 2019 Mar 1;142(3):496-498. doi: 10.1093/brain/awz010. No abstract available.

PMID:
30810212
15.

Imaging Markers of Progression in Parkinson's Disease.

Strafella AP, Bohnen NI, Pavese N, Vaillancourt DE, van Eimeren T, Politis M, Tessitore A, Ghadery C, Lewis S; IPMDS‐Neuroimaging Study Group.

Mov Disord Clin Pract. 2018 Oct 9;5(6):586-596. doi: 10.1002/mdc3.12673. eCollection 2018 Nov-Dec. Review.

16.

Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease.

Yilmaz R, Strafella AP, Bernard A, Schulte C, van den Heuvel L, Schneiderhan-Marra N, Knorpp T, Joos TO, Leypoldt F, Geritz J, Hansen C, Heinzel S, Apel A, Gasser T, Lang AE, Berg D, Maetzler W, Marras C.

Front Neurol. 2018 Dec 21;9:1123. doi: 10.3389/fneur.2018.01123. eCollection 2018.

17.

Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway.

Cho SS, Christopher L, Koshimori Y, Li C, Lang AE, Houle S, Strafella AP.

Neurobiol Dis. 2019 Apr;124:176-182. doi: 10.1016/j.nbd.2018.11.022. Epub 2018 Nov 22.

PMID:
30471418
18.

Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.

Ghadery C, Valli M, Mihaescu A, Strafella R, Navalpotro I, Kim J, Strafella AP.

Int Rev Neurobiol. 2018;141:365-404. doi: 10.1016/bs.irn.2018.07.030. Epub 2018 Aug 13. Review.

PMID:
30314604
19.

Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.

Fiorenzato E, Biundo R, Cecchin D, Frigo AC, Kim J, Weis L, Strafella AP, Antonini A.

J Alzheimers Dis. 2018;66(1):229-237. doi: 10.3233/JAD-180390.

PMID:
30282359
20.

[18 F]AV-1451 binding and postmortem pathology of CBD.

Coakeley S, Ang LC, Jansen GH, Cho SS, Lang AE, Houle S, Kalia LV, Strafella AP.

Mov Disord. 2018 Aug;33(8):1360-1361. doi: 10.1002/mds.27356. Epub 2018 Aug 23. No abstract available.

PMID:
30136331
21.

Brain degeneration in Parkinson's disease patients with cognitive decline: a coordinate-based meta-analysis.

Mihaescu AS, Masellis M, Graff-Guerrero A, Kim J, Criaud M, Cho SS, Ghadery C, Valli M, Strafella AP.

Brain Imaging Behav. 2019 Aug;13(4):1021-1034. doi: 10.1007/s11682-018-9922-0.

PMID:
29971686
22.

PET/CT of Dementia.

Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.

AJR Am J Roentgenol. 2018 Aug;211(2):246-259. doi: 10.2214/AJR.18.19822. Epub 2018 Jun 27. Review.

PMID:
29949415
23.

New Imaging Markers for Movement Disorders.

Ghadery C, Strafella AP.

Curr Neurol Neurosci Rep. 2018 Apr 3;18(5):22. doi: 10.1007/s11910-018-0830-x. Review.

PMID:
29616343
24.

Dynamic functional connectivity in Parkinson's disease patients with mild cognitive impairment and normal cognition.

Díez-Cirarda M, Strafella AP, Kim J, Peña J, Ojeda N, Cabrera-Zubizarreta A, Ibarretxe-Bilbao N.

Neuroimage Clin. 2017 Dec 9;17:847-855. doi: 10.1016/j.nicl.2017.12.013. eCollection 2018.

25.

New advances in tau imaging in parkinsonism.

Valli M, Strafella AP.

Int Rev Psychiatry. 2017 Dec;29(6):628-635. doi: 10.1080/09540261.2017.1396446. Epub 2017 Dec 5. Review.

PMID:
29206491
26.

Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans.

Malik S, Jacobs M, Cho SS, Boileau I, Blumberger D, Heilig M, Wilson A, Daskalakis ZJ, Strafella AP, Zangen A, Le Foll B.

Brain Imaging Behav. 2018 Oct;12(5):1306-1317. doi: 10.1007/s11682-017-9800-1.

PMID:
29170944
27.

Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment.

Knezevic D, Verhoeff NPL, Hafizi S, Strafella AP, Graff-Guerrero A, Rajji T, Pollock BG, Houle S, Rusjan PM, Mizrahi R.

J Cereb Blood Flow Metab. 2018 Nov;38(11):1885-1895. doi: 10.1177/0271678X17741395. Epub 2017 Nov 14.

28.

Abnormal intrinsic brain functional network dynamics in Parkinson's disease.

Kim J, Criaud M, Cho SS, Díez-Cirarda M, Mihaescu A, Coakeley S, Ghadery C, Valli M, Jacobs MF, Houle S, Strafella AP.

Brain. 2017 Nov 1;140(11):2955-2967. doi: 10.1093/brain/awx233. No abstract available.

29.

Contribution of transcranial magnetic stimulation to assessment of brain connectivity and networks.

Hallett M, Di Iorio R, Rossini PM, Park JE, Chen R, Celnik P, Strafella AP, Matsumoto H, Ugawa Y.

Clin Neurophysiol. 2017 Nov;128(11):2125-2139. doi: 10.1016/j.clinph.2017.08.007. Epub 2017 Sep 5. Review.

30.

[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP.

Coakeley S, Cho SS, Koshimori Y, Rusjan P, Ghadery C, Kim J, Lang AE, Houle S, Strafella AP.

Brain Struct Funct. 2018 Mar;223(2):589-595. doi: 10.1007/s00429-017-1507-y. Epub 2017 Sep 7.

PMID:
28884232
31.

Imaging behavioural complications of Parkinson's disease.

Valli M, Mihaescu A, Strafella AP.

Brain Imaging Behav. 2019 Apr;13(2):323-332. doi: 10.1007/s11682-017-9764-1. Review.

PMID:
28856542
32.

Imaging tau pathology in Parkinsonisms.

Coakeley S, Strafella AP.

NPJ Parkinsons Dis. 2017 Jun 29;3:22. doi: 10.1038/s41531-017-0023-3. eCollection 2017. Review.

33.

Testing the physiological plausibility of conflicting psychological models of response inhibition: A forward inference fMRI study.

Criaud M, Longcamp M, Anton JL, Nazarian B, Roth M, Sescousse G, Strafella AP, Ballanger B, Boulinguez P.

Behav Brain Res. 2017 Aug 30;333:192-202. doi: 10.1016/j.bbr.2017.06.030. Epub 2017 Jun 21.

PMID:
28647596
34.

Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function.

Mabrouk R, Strafella AP, Knezevic D, Ghadery C, Mizrahi R, Gharehgazlou A, Koshimori Y, Houle S, Rusjan P.

PLoS One. 2017 May 17;12(5):e0177785. doi: 10.1371/journal.pone.0177785. eCollection 2017.

35.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EWC, Masellis M, Strafella AP, Lang AE, Bassett AS.

Brain. 2017 May 1;140(5):1371-1383. doi: 10.1093/brain/awx053.

PMID:
28369257
36.

Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, Masellis M.

Transl Neurodegener. 2017 Mar 28;6:8. doi: 10.1186/s40035-017-0076-6. eCollection 2017. Review.

37.

Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Coakeley S, Cho SS, Koshimori Y, Rusjan P, Harris M, Ghadery C, Kim J, Lang AE, Wilson A, Houle S, Strafella AP.

J Cereb Blood Flow Metab. 2017 Sep;37(9):3150-3160. doi: 10.1177/0271678X16683695. Epub 2016 Dec 22.

38.

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.

Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-Pardo JÁ, Cilia R, Ballanger B, Niethammer M, Stoessl JA; IPMDS-Neuroimaging Study Group.

Mov Disord. 2017 Feb;32(2):181-192. doi: 10.1002/mds.26907. Epub 2017 Feb 2. Review.

39.

The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations.

Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M, Rusjan PM, Houle S, Fox SH.

Mov Disord Clin Pract. 2017 Jan 23;4(5):698-709. doi: 10.1002/mdc3.12466. eCollection 2017 Sep-Oct.

40.

Microglial activation in Parkinson's disease using [18F]-FEPPA.

Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, Houle S, Strafella AP.

J Neuroinflammation. 2017 Jan 11;14(1):8. doi: 10.1186/s12974-016-0778-1.

41.

Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease.

Koshimori Y, Cho SS, Criaud M, Christopher L, Jacobs M, Ghadery C, Coakeley S, Harris M, Mizrahi R, Hamani C, Lang AE, Houle S, Strafella AP.

Front Aging Neurosci. 2016 Nov 10;8:259. eCollection 2016.

42.

Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes.

Cho SS, Aminian K, Li C, Lang AE, Houle S, Strafella AP.

Hum Brain Mapp. 2017 Jan;38(1):283-292. doi: 10.1002/hbm.23360. Epub 2016 Aug 29.

PMID:
27571419
43.

Slowness in Movement Initiation is Associated with Proactive Inhibitory Network Dysfunction in Parkinson's Disease.

Criaud M, Poisson A, Thobois S, Metereau E, Redouté J, Ibarrola D, Baraduc P, Broussolle E, Strafella AP, Ballanger B, Boulinguez P.

J Parkinsons Dis. 2016 Apr 2;6(2):433-40. doi: 10.3233/JPD-150750.

PMID:
27061065
44.

Contribution of insula in Parkinson's disease: A quantitative meta-analysis study.

Criaud M, Christopher L, Boulinguez P, Ballanger B, Lang AE, Cho SS, Houle S, Strafella AP.

Hum Brain Mapp. 2016 Apr;37(4):1375-92. doi: 10.1002/hbm.23109. Epub 2016 Jan 22.

45.

Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.

Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, Christopher L, Hamani C, Lang AE, Wilson AA, Houle S, Strafella AP.

PLoS One. 2015 Sep 18;10(9):e0138721. doi: 10.1371/journal.pone.0138721. eCollection 2015.

46.

Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.

Aracil-Bolaños I, Strafella AP.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S101-5. doi: 10.1016/j.parkreldis.2015.08.003. Epub 2015 Aug 12. Review.

47.

Imaging pathological tau in atypical parkinsonian disorders.

Coakeley S, Strafella AP.

Curr Opin Neurol. 2015 Aug;28(4):447-52. doi: 10.1097/WCO.0000000000000210. Review.

48.

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment.

Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P.

Lancet Neurol. 2015 May;14(5):518-31. doi: 10.1016/S1474-4422(15)00019-8. Epub 2015 Apr 12. Review.

PMID:
25895932
49.

Apathy: who cares?

Krack P, Pagonabarraga J, Strafella AP, Kulisevsky J.

Lancet Neurol. 2015 May;14(5):465. doi: 10.1016/S1474-4422(15)00031-9. Epub 2015 Apr 12. No abstract available.

PMID:
25895927
50.

Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors.

Sierra M, Carnicella S, Strafella AP, Bichon A, Lhommée E, Castrioto A, Chabardes S, Thobois S, Krack P.

J Parkinsons Dis. 2015;5(3):625-36. doi: 10.3233/JPD-150535. Review.

PMID:
25870025

Supplemental Content

Loading ...
Support Center